Clinical Trial Update: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a sequence of interleukin-2 with ipilimumab followed by nivolumab for stage III or IV melanoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Proleukin (aldesleukin)
• Yervoy (ipilimumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma Stage III, Melanoma Stage IV | Phase 2 | Status: RECRUITING